Headlines about Bruker Corporation (NASDAQ:BRKR) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bruker Corporation earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 47.1239763499958 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Derma Sciences (DSCI) and Bruker Corporation (BRKR) Head to Head Survey (americanbankingnews.com)
- Analysts Expect Bruker Corporation (BRKR) Will Announce Quarterly Sales of $506.92 Million (americanbankingnews.com)
- Bruker Corporation : SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bruker Corporation (BRKR) (4-traders.com)
- Bruker Announces Quarterly Dividend (finance.yahoo.com)
Several research firms recently commented on BRKR. Citigroup Inc. upped their target price on shares of Bruker Corporation from $29.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Cowen and Company reiterated a “hold” rating and set a $29.00 target price on shares of Bruker Corporation in a research note on Friday, November 3rd. Zacks Investment Research upgraded shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Wednesday, November 8th. Bank of America Corporation upgraded shares of Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a research note on Friday, November 3rd. Finally, J P Morgan Chase & Co upgraded shares of Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $29.64.
Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.83%. The company had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. During the same quarter in the prior year, the company posted $0.32 EPS. The business’s revenue was up 10.6% on a year-over-year basis. research analysts forecast that Bruker Corporation will post 1.19 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 22nd. Stockholders of record on Monday, December 4th will be issued a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.47%. The ex-dividend date is Friday, December 1st. Bruker Corporation’s payout ratio is 17.02%.
In other news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 35.20% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Bruker Corporation (BRKR) Receiving Somewhat Positive Press Coverage, Report Finds” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/11/20/bruker-corporation-brkr-receiving-somewhat-positive-press-coverage-report-finds.html.
About Bruker Corporation
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.